Roche has received approval from the United States Food and Drug Administration for its Cobas qualitative testing systems to confirm HIV diagnosis, the Swiss pharmaceuticals company said on Tuesday.

Roche has announced that the U.S. Food and Drug Administration has categorized its Ionify 25-Hydroxy Vitamin D total assay as ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) on Monday reported that a drug combination including its investigational giredestrant met the main goals in a late-stage clinical trial for breast ...

Roche Holding AG will move an experimental obesity shot into late-stage trials next year in a bid to challenge leaders in the booming market for weight-loss medicines. The drug, known as CT-388, ...

ZURICH (Reuters) -Roche Chief Executive Thomas Schinecker and other senior executives from the Swiss pharmaceuticals industry will meet with the government on Monday to discuss the threat U.S. tariffs ...

Roche plans to move one of its weight-loss treatment candidates to late-stage trials next year, as the Swiss pharmaceutical group aims to become a top-three player in the booming market. The group ...

Roche on Thursday agreed to acquire 89bio, wagering that a medicine the biotechnology company is developing could offer a new way to treat a common liver condition. The Swiss pharmaceutical giant will ...

The last time I spoke about 89bio (NASDAQ:ETNB) it was with respect to a Seeking Alpha article entitled "89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward." With respect to this ...

There are two FDA-approved medications for the metabolic disorder known as MASH. Roche is paying $2.4 billion to acquire 89bio and its late-stage MASH drug, giving the Swiss pharmaceutical giant the ...

Roche targets liver disease treatments with acquisition Deal includes $14.50 a share, potential milestone payments up to $6.00 a share Roche flags potential to treat obesity-related conditions The ...

Basel: Roche has announced that it has entered into a definitive merger agreement to acquire 89bio, Inc., a publicly listed clinical-stage biopharmaceutical company. 89bio’s pegozafermin is a FGF21 ...

FRANKFURT (Reuters) - Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments that complement an intense push in the area of weight ...